Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) Price Target at $6.60

Context Therapeutics Inc. (NASDAQ:CNTX) has received an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $6.60.

Several equities analysts have recently commented on CNTX shares. Piper Sandler increased their price objective on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Tuesday, March 24th. Wall Street Zen lowered Context Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Monday. Finally, Guggenheim reiterated a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a research report on Tuesday, March 24th.

Context Therapeutics Stock Down 2.6%

Shares of NASDAQ CNTX opened at $2.26 on Wednesday. The firm has a market capitalization of $207.65 million, a P/E ratio of -5.95 and a beta of 1.82. The stock’s 50-day simple moving average is $2.61 and its two-hundred day simple moving average is $1.84. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). As a group, research analysts anticipate that Context Therapeutics will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Several institutional investors have recently modified their holdings of CNTX. Virtu Financial LLC purchased a new stake in Context Therapeutics during the 4th quarter valued at about $43,000. Quadrature Capital Ltd purchased a new stake in Context Therapeutics during the 4th quarter valued at about $68,000. Clear Harbor Asset Management LLC boosted its holdings in Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares during the period. Citadel Advisors LLC purchased a new stake in Context Therapeutics during the 3rd quarter valued at about $100,000. Finally, XTX Topco Ltd boosted its holdings in Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after acquiring an additional 91,008 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.